Bayshore Pharmaceuticals has recalled 4,578 bottles of Metformin Hydrochloride Extended-Release Tablets (USP), a prescription medication used to manage blood sugar in patients with type 2 diabetes. The recall includes 594 bottles of 500 mg tablets and 3,984 bottles of 750 mg tablets due to deviations from Current Good Manufacturing Practice (CGMP) requirements. Because these medications did not meet specific manufacturing standards, consumers should consult their healthcare provider or pharmacist for guidance on how to safely transition to an alternative treatment before stopping the medication.
The recall was initiated due to manufacturing deviations (CGMP), which means the products may not meet the quality and safety standards required by the FDA. Stopping a diabetes medication without a replacement can pose immediate health risks, so patients must coordinate with a healthcare professional before returning the product.
Consult healthcare provider and return to pharmacy.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.